Monogenetic Disease Therapy Market Report 2026

The monogenetic disease therapy market size has grown strongly in recent years. It will grow from $28.3 billion in 2025 to $31.08 billion in 2026 at a compound annual growth rate (CAGR) of 9.8%. The growth in the historic period can be attributed to human genome research progress, early gene therapy trials, rise in rare disease diagnosis, orphan drug incentives, advances in viral vectors.

The monogenetic disease therapy market size is expected to see rapid growth in the next few years. It will grow to $45.58 billion in 2030 at a compound annual growth rate (CAGR) of 10%. The growth in the forecast period can be attributed to growth in gene editing platforms, expansion of rare disease pipelines, higher genetic screening rates, increased personalized therapy funding, broader regulatory approvals. Major trends in the forecast period include single gene targeted therapies, gene replacement treatment programs, rna based genetic treatments, rare disease gene correction, precision genetic drug design.

The increasing adoption of precision and personalized medicine is expected to drive the growth of the monogenetic disease therapy market going forward. Precision and personalized medicine is a medical approach that customizes disease prevention, diagnosis, and treatment based on an individual’s unique genetic, molecular, or lifestyle characteristics to enhance therapeutic effectiveness and reduce adverse effects. The growth of precision and personalized medicine is driven by healthcare providers and patients seeking individualized treatments that maximize efficacy, minimize side effects, and address specific genetic, molecular, or lifestyle factors. Monogenetic disease therapy supports precision and personalized medicine by targeting a patient’s specific genetic mutation, enabling highly customized and effective treatment solutions. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based hospital and health care organization, the FDA approved 16 new personalized treatments for rare disease patients in 2023, up from six approvals in 2022. Therefore, the rising adoption of precision and personalized medicine is accelerating the growth of the monogenetic disease therapy market.

Leading companies operating in the monogenetic disease therapy market are focusing on developing innovative gene therapies, such as Duchenne muscular dystrophy (DMD)-targeted protocols, to slow disease progression and improve long-term patient outcomes. Duchenne muscular dystrophy-targeted protocols are structured clinical or therapeutic guidelines specifically designed to diagnose, monitor, and manage patients with Duchenne muscular dystrophy, focusing on slowing disease progression, improving muscle function, and addressing associated complications. For example, in January 2026, Sarepta Therapeutics Inc, a US-based biopharmaceutical company, launched Elevidys for ambulatory patients aged four and older with DMD, reporting up to a 73% reduction in the rate of functional decline over three years compared with an external control group, highlighting the importance of early intervention to alter disease course and improve quality of life.

In October 2024, Ocuphire Pharma Inc., a US-based clinical-stage ophthalmic biopharmaceutical company, acquired Opus Genetics Inc. for an undisclosed amount. With this acquisition, Ocuphire aimed to establish a leading gene therapy franchise by combining its late-stage drug development expertise with Opus Genetics’ pipeline of AAV-based gene therapy candidates targeting conditions such as Leber congenital amaurosis and other inherited retinal disorders. Opus Genetics Inc. is a US-based clinical-stage gene therapy company focused on monogenetic disease therapy, specializing in the development of AAV-based, one-time treatments for rare inherited retinal diseases caused by single-gene mutations.

Major companies operating in the monogenetic disease therapy market are Pfizer Inc., Sanofi S.A., Astellas Pharma Inc., Vertex Pharmaceuticals Incorporated, Sarepta Therapeutics Inc., Ptc therapeutics inc., Crispr therapeutics ag, CRISPR Therapeutics, Voyager Therapeutics Inc., Oxford Biomedica plc, REGENXBIO INC., Arcturus therapeutics holdings inc., Editas medicine Inc., American Gene Technologies, UniQure NV., MeiraGTx Limited, Prime medicine, Abeona therapeutics Inc., Blue Cross Blue Shield Association, Rocket pharmaceuticals Inc.

Tariffs on viral vectors, specialized biologic inputs, and advanced therapy manufacturing materials are affecting the monogenetic disease therapy market by increasing production and development costs. Gene and RNA based therapy segments are most impacted where cross border sourcing of biotech materials and reagents is common, especially across north america and europe. Higher import duties can raise therapy manufacturing expenses and treatment pricing. However, tariffs are also encouraging regional biomanufacturing capacity and local supply chain development. This supports domestic gene therapy producers and specialized biotech suppliers.

The monogenetic disease therapy market research report is one of a series of new reports that provides monogenetic disease therapy market statistics, including monogenetic disease therapy industry global market size, regional shares, competitors with a monogenetic disease therapy market share, detailed monogenetic disease therapy market segments, market trends and opportunities, and any further data you may need to thrive in the monogenetic disease therapy industry. This monogenetic disease therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Monogenetic disease therapy refers to advanced medical treatments designed to target diseases caused by mutations or defects in a single gene, by correcting, replacing, silencing, or compensating for the abnormal gene or its resulting protein function. These therapies include gene therapy, RNA-based interventions, enzyme replacement therapies, and targeted small-molecule drugs, all aimed at addressing the underlying genetic cause rather than merely managing clinical symptoms.

The primary types of monogenetic disease therapy include pharmacological, surgical, blood transfusion, gene therapies, and other therapy types. Pharmacological therapies refer to treatment approaches that use drugs to control symptoms or alter disease progression in patients affected by single-gene disorders. These therapies are categorized based on inheritance patterns such as autosomal and chromosomal. They are used for conditions including cystic fibrosis, sickle cell anemia, phenylketonuria, and other applications. They are distributed through hospital pharmacies, retail pharmacies, and online pharmacies, and are utilized by end users such as clinics, hospitals, diagnostic centres, home healthcare providers, and other end users.

The monogenetic disease therapy market includes revenues earned by entities through gene replacement therapies, gene editing therapies, RNA-based therapies, cell-based gene therapies, and gene silencing or modulation therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.